Fig 1: Glucose and insulin response in db/db mice treated with GLP-1 analogs. (A and B) Single subcutaneous dose of GLP-1 analogs in db/db mice. Dosing is at time 0 h. (C) GLP-1 analogs were dosed subcutaneously daily for 42 days. Insulin was measured on Day 43. Significance was calculated for M4 vs semaglutide using a mixed models for repeated measures (MMRM) analysis (A and B), and for M4 vs vehicle and semaglutide using one-way ANOVA (C). ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. M4, ecnoglutide. Mean and standard deviation (SD) are plotted.
Fig 2: Body weight response in db/db mice and DIO SD rats treated with GLP-1 analogs. (A–C) Male db/db mice administered vehicle, ecnoglutide (M4), or semaglutide by s.c. injection once daily for 42 days. (D) Male DIO SD rats dosed with vehicle, ecnoglutide (M4, 0.025 mg/kg), or semaglutide (0.025 mg/kg) s.c. once daily for 21 days, after which the active treatment groups were switched to dosing with the other compound for 7 days. Grey box indicates switched treatment period. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗∗p < 0.0001. Mean and SD are plotted for B–D.
Fig 3: GLP-1 receptor signaling pathways induced by GLP-1 peptide analogs. DiscoverX Cell Signaling Assays were used to evaluate GLP-1 analogs for (A) cAMP induction in HitHunter hGLP1R-CHO-K1 cells (B) β-arrestin recruitment in PathHunter β-Arrestin hGLP1R-CHO-K1 cells and (C) β-arrestin-mediated GLP-1 receptor internalization in PathHunter Activated GPCR Internalization hGLP1R-U2OS cells. Percent activity was determined from the chemiluminescent readout of the assays. Mean and standard deviation are plotted.
Supplier Page from Sino Biological, Inc. for Human GLP-1R / GLP1R Protein (Fc Tag)